FDA granted an accelerated approval to Blincyto (blinatumomab) to treat adults and children with B-cell precursor acute lymphoblastic leukemia who are in remission but still have minimal residual disease.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
